Published in Int J Biochem Cell Biol on March 07, 2007
p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer (2009) 9.21
Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell (2012) 3.65
Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining. Nat Struct Mol Biol (2010) 3.27
Examination of the expanding pathways for the regulation of p21 expression and activity. Cell Signal (2010) 2.44
UHRF1 binds G9a and participates in p21 transcriptional regulation in mammalian cells. Nucleic Acids Res (2008) 1.80
Nonhistone protein acetylation as cancer therapy targets. Expert Rev Anticancer Ther (2010) 1.45
Deacetylase-independent function of HDAC3 in transcription and metabolism requires nuclear receptor corepressor. Mol Cell (2013) 1.44
The cyclin-dependent kinase inhibitor p21 is a crucial target for histone deacetylase 1 as a regulator of cellular proliferation. Mol Cell Biol (2009) 1.42
Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy. Oncogene (2011) 1.38
Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biologics (2013) 1.38
p21(WAF1) gene promoter is epigenetically silenced by CTIP2 and SUV39H1. Oncogene (2009) 1.35
A large scale shRNA barcode screen identifies the circadian clock component ARNTL as putative regulator of the p53 tumor suppressor pathway. PLoS One (2009) 1.29
Histone deacetylase controls adult stem cell aging by balancing the expression of polycomb genes and jumonji domain containing 3. Cell Mol Life Sci (2010) 1.25
Epigenomics and breast cancer. Pharmacogenomics (2008) 1.23
Differential effects of sulforaphane on histone deacetylases, cell cycle arrest and apoptosis in normal prostate cells versus hyperplastic and cancerous prostate cells. Mol Nutr Food Res (2011) 1.22
The polycomb group protein BMI1 is a transcriptional target of HDAC inhibitors. Cell Cycle (2010) 1.17
Chfr is linked to tumour metastasis through the downregulation of HDAC1. Nat Cell Biol (2009) 1.12
Specific activity of class II histone deacetylases in human breast cancer cells. Mol Cancer Res (2008) 1.07
Epigenetic control of epithelial-mesenchymal-transition in human cancer. Mol Clin Oncol (2012) 1.03
Mule determines the apoptotic response to HDAC inhibitors by targeted ubiquitination and destruction of HDAC2. Genes Dev (2011) 1.03
DeltaNp63, a target of DEC1 and histone deacetylase 2, modulates the efficacy of histone deacetylase inhibitors in growth suppression and keratinocyte differentiation. J Biol Chem (2011) 1.03
Combination therapy with vidaza and entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model. Cancer Res (2011) 1.01
Histone deacetylase inhibitors and cell death. Cell Mol Life Sci (2014) 1.00
Histone deacetylase inhibitors SAHA and sodium butyrate block G1-to-S cell cycle progression in neurosphere formation by adult subventricular cells. BMC Neurosci (2011) 1.00
TP53 status and response to treatment in breast cancers. J Biomed Biotechnol (2011) 0.99
Inositol pyrophosphates regulate cell growth and the environmental stress response by activating the HDAC Rpd3L. Cell Rep (2013) 0.98
Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC. Virchows Arch (2011) 0.97
Antagonistic pleiotropy and p53. Mech Ageing Dev (2008) 0.97
AP-2gamma promotes proliferation in breast tumour cells by direct repression of the CDKN1A gene. EMBO J (2009) 0.97
Overview of major classes of plant-derived anticancer drugs. Int J Biomed Sci (2009) 0.96
Protein kinase C (PKC) delta suppresses keratinocyte proliferation by increasing p21(Cip1) level by a KLF4 transcription factor-dependent mechanism. J Biol Chem (2011) 0.96
The PARP inhibitor PJ34 causes a PARP1-independent, p21 dependent mitotic arrest. DNA Repair (Amst) (2011) 0.94
Sulforaphane induction of p21(Cip1) cyclin-dependent kinase inhibitor expression requires p53 and Sp1 transcription factors and is p53-dependent. J Biol Chem (2012) 0.94
Grape seed extract upregulates p21 (Cip1) through redox-mediated activation of ERK1/2 and posttranscriptional regulation leading to cell cycle arrest in colon carcinoma HT29 cells. Mol Carcinog (2011) 0.93
Quercetin enhances the antitumor activity of trichostatin A through upregulation of p53 protein expression in vitro and in vivo. PLoS One (2013) 0.92
Adult hematopoietic stem cells require NKAP for maintenance and survival. Blood (2010) 0.92
Deacetylase inhibitors - focus on non-histone targets and effects. World J Biol Chem (2010) 0.90
C-terminal binding protein and poly(ADP)ribose polymerase 1 contribute to repression of the p21(waf1/cip1) promoter. Oncogene (2010) 0.89
Epigenetic modifications and p21-cyclin B1 nexus in anticancer effect of histone deacetylase inhibitors in combination with silibinin on non-small cell lung cancer cells. Epigenetics (2012) 0.89
Pituitary gland development and disease: from stem cell to hormone production. Curr Top Dev Biol (2013) 0.88
ATM phosphorylates ZBP-89 at Ser202 to potentiate p21waf1 induction by butyrate. Biochem Biophys Res Commun (2007) 0.88
Inhibition of DNA methyltransferase activity and expression by treatment with the pan-deacetylase inhibitor panobinostat in hepatocellular carcinoma cell lines. BMC Cancer (2012) 0.88
Activation of p21 by HDAC inhibitors requires acetylation of H2A.Z. PLoS One (2013) 0.87
Combination therapy with the histone deacetylase inhibitor LBH589 and radiation is an effective regimen for prostate cancer cells. PLoS One (2013) 0.87
MS-275 synergistically enhances the growth inhibitory effects of RAMBA VN/66-1 in hormone-insensitive PC-3 prostate cancer cells and tumours. Br J Cancer (2008) 0.86
The effects of the histone deacetylase inhibitor romidepsin (FK228) are enhanced by aspirin (ASA) in COX-1 positive ovarian cancer cells through augmentation of p21. Cancer Biol Ther (2010) 0.86
Manipulating protein acetylation in breast cancer: a promising approach in combination with hormonal therapies? J Biomed Biotechnol (2010) 0.86
Selenium-containing histone deacetylase inhibitors for melanoma management. Cancer Biol Ther (2012) 0.86
Mechanism of growth inhibition of prostate cancer xenografts by valproic acid. J Biomed Biotechnol (2012) 0.85
Endoplasmic reticulum stress plays a pivotal role in cell death mediated by the pan-deacetylase inhibitor panobinostat in human hepatocellular cancer cells. Transl Oncol (2013) 0.85
Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression. Breast Cancer Res (2015) 0.84
Histone deacetylases in neural stem cells and induced pluripotent stem cells. J Biomed Biotechnol (2011) 0.84
Myelodysplastic syndrome and histone deacetylase inhibitors: "to be or not to be acetylated"? J Biomed Biotechnol (2011) 0.83
Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine. Epigenetics (2015) 0.83
PRMT6 increases cytoplasmic localization of p21CDKN1A in cancer cells through arginine methylation and makes more resistant to cytotoxic agents. Oncotarget (2015) 0.83
A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors. Cancer Biol Ther (2013) 0.83
Therapeutic targeting of tumor suppressor genes. Cancer (2014) 0.82
Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer. BMC Cancer (2012) 0.82
Cyclin D1 degradation and p21 induction contribute to growth inhibition of colorectal cancer cells induced by epigallocatechin-3-gallate. J Cancer Res Clin Oncol (2012) 0.81
SIRT1 and SIRT2 inhibition impairs pediatric soft tissue sarcoma growth. Cell Death Dis (2014) 0.81
Zyflamend, a polyherbal mixture, down regulates class I and class II histone deacetylases and increases p21 levels in castrate-resistant prostate cancer cells. BMC Complement Altern Med (2014) 0.81
An epithelial marker promoter induction screen identifies histone deacetylase inhibitors to restore epithelial differentiation and abolishes anchorage independence growth in cancers. Cell Death Discov (2016) 0.80
CD1d induction in solid tumor cells by histone deacetylase inhibitors through inhibition of HDAC1/2 and activation of Sp1. Epigenetics (2012) 0.80
Characterization of cells resistant to the potent histone deacetylase inhibitor spiruchostatin B (SP-B) and effect of overexpressed p21waf1/cip1 on the SP-B resistance or susceptibility of human leukemia cells. Int J Oncol (2012) 0.80
The Role of Sulforaphane in Epigenetic Mechanisms, Including Interdependence between Histone Modification and DNA Methylation. Int J Mol Sci (2015) 0.80
EBV-positive Hodgkin lymphoma is associated with suppression of p21cip1/waf1 and a worse prognosis. Mol Cancer (2010) 0.80
Histone deacetylase inhibition and the regulation of cell growth with particular reference to liver pathobiology. J Cell Mol Med (2009) 0.80
Sulforaphane-induced transcription of thioredoxin reductase in lens: possible significance against cataract formation. Clin Ophthalmol (2013) 0.79
Role of histone deacetylase activity in the developing lateral line neuromast of zebrafish larvae. Exp Mol Med (2014) 0.78
The effect of valproic acid on bovine oocyte maturation and early embryonic development in vitro. Cytotechnology (2013) 0.78
Thymoquinone hydrazone derivatives cause cell cycle arrest in p53-competent colorectal cancer cells. Exp Ther Med (2010) 0.77
Inhibition of Plk1 and Cyclin B1 expression results in panobinostat-induced G₂ delay and mitotic defects. Sci Rep (2013) 0.77
Lhx4 deficiency: increased cyclin-dependent kinase inhibitor expression and pituitary hypoplasia. Mol Endocrinol (2015) 0.77
Histone Deacetylase Inhibitors as Anticancer Drugs. Int J Mol Sci (2017) 0.77
Survival of primary, but not of cancer cells after combined Plk1-HDAC inhibition. Oncotarget (2015) 0.76
RAD51 potentiates synergistic effects of chemotherapy with PCI-24781 and cis-diamminedichloroplatinum on gastric cancer. World J Gastroenterol (2014) 0.76
ΔNp63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer. Cancer Cell (2016) 0.76
Marine-derive chromopeptide A, a novel class I HDAC inhibitor, suppresses human prostate cancer cell proliferation and migration. Acta Pharmacol Sin (2017) 0.75
PAI-1 Expression Is Required for HDACi-Induced Proliferative Arrest in ras-Transformed Renal Epithelial Cells. Int J Cell Biol (2011) 0.75
Butyrate Inhibits Cancerous HCT116 Colon Cell Proliferation but to a Lesser Extent in Noncancerous NCM460 Colon Cells. Nutrients (2017) 0.75
The histone deacetylase inhibitor trichostatin a decreases lymphangiogenesis by inducing apoptosis and cell cycle arrest via p21-dependent pathways. BMC Cancer (2016) 0.75
Epigenetic and miRNAs Dysregulation in Prostate Cancer: The role of Nutraceuticals. Anticancer Agents Med Chem (2016) 0.75
A Microchip for Integrated Single-Cell Gene Expression Profiling and Genotoxicity Detection. Sensors (Basel) (2016) 0.75
p21(WAF1) modulates drug-induced apoptosis and cell cycle arrest in B-cell precursor acute lymphoblastic leukemia. Cell Cycle (2015) 0.75
Atypical role of sprouty in p21 dependent inhibition of cell proliferation in colorectal cancer. Mol Carcinog (2015) 0.75
Panobinostat as Pan-deacetylase Inhibitor for the Treatment of Pancreatic Cancer: Recent Progress and Future Prospects. Oncol Ther (2016) 0.75
Histone Deacetylase Inhibitors Increase p27(Kip1) by Affecting Its Ubiquitin-Dependent Degradation through Skp2 Downregulation. Oxid Med Cell Longev (2015) 0.75
Platelet activating factor-induced expression of p21 is correlated with histone acetylation. Sci Rep (2017) 0.75
Efficacy of the dietary histone deacetylase inhibitor butyrate alone or in combination with vitamin A against proliferation of MCF-7 human breast cancer cells. Braz J Med Biol Res (2012) 0.75
Teng-Long-Bu-Zhong-Tang induces p21-dependent cell senescence in colorectal carcinoma LS174T cells via histone acetylation. J Exp Pharmacol (2017) 0.75
The lauric acid-activated signaling prompts apoptosis in cancer cells. Cell Death Discov (2017) 0.75
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron (2006) 2.55
Thymoquinone: a promising anti-cancer drug from natural sources. Int J Biochem Cell Biol (2005) 1.67
Thymoquinone extracted from black seed triggers apoptotic cell death in human colorectal cancer cells via a p53-dependent mechanism. Int J Oncol (2004) 1.60
Presence of homozygous KIT exon 11 mutations is strongly associated with malignant clinical behavior in gastrointestinal stromal tumors. Lab Invest (2007) 1.56
miRNA-26b Overexpression in Ulcerative Colitis-associated Carcinogenesis. Inflamm Bowel Dis (2015) 1.47
Spectrum of KIT/PDGFRA/BRAF mutations and Phosphatidylinositol-3-Kinase pathway gene alterations in gastrointestinal stromal tumors (GIST). Cancer Lett (2011) 1.41
Hypermethylation and loss of expression of glutathione peroxidase-3 in Barrett's tumorigenesis. Neoplasia (2005) 1.38
The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells. Mol Cancer Ther (2012) 1.33
Lack of p53 augments thymoquinone-induced apoptosis and caspase activation in human osteosarcoma cells. Cancer Biol Ther (2007) 1.23
K-ras mutation detection in colorectal cancer using the Pyrosequencing technique. Pathol Res Pract (2007) 1.21
Reactive oxygen species mediate thymoquinone-induced apoptosis and activate ERK and JNK signaling. Apoptosis (2010) 1.21
Thymoquinone triggers inactivation of the stress response pathway sensor CHEK1 and contributes to apoptosis in colorectal cancer cells. Cancer Res (2008) 1.11
Thymoquinone reduces mouse colon tumor cell invasion and inhibits tumor growth in murine colon cancer models. J Cell Mol Med (2008) 1.10
Epigenetic regulation in murine offspring as a novel mechanism for transmaternal asthma protection induced by microbes. J Allergy Clin Immunol (2011) 1.10
KIT 1530ins6 mutation defines a subset of predominantly malignant gastrointestinal stromal tumors of intestinal origin. Hum Pathol (2003) 1.08
Aberrant methylation of DAPK in long-standing ulcerative colitis and ulcerative colitis-associated carcinoma. Pathol Res Pract (2010) 1.08
Histopathologic features and microsatellite instability of cancers of the papilla of vater and their precursor lesions. Am J Surg Pathol (2009) 1.07
Immunohistochemical and molecular analysis of p53, RB, and PTEN in malignant peripheral nerve sheath tumors. Virchows Arch (2001) 1.06
Overexpression of fatty acid synthase in chemically and hormonally induced hepatocarcinogenesis of the rat. Lab Invest (2005) 1.06
DAPK promotor methylation is an early event in colorectal carcinogenesis. Cancer Lett (2005) 1.04
The pan-deacetylase inhibitor panobinostat inhibits growth of hepatocellular carcinoma models by alternative pathways of apoptosis. Cell Oncol (2010) 1.04
Tumor fibroblast-derived epiregulin promotes growth of colitis-associated neoplasms through ERK. J Clin Invest (2013) 1.03
Gastrointestinal stromal tumors of the vermiform appendix: clinicopathologic, immunohistochemical, and molecular study of 2 cases with literature review. Hum Pathol (2008) 1.03
Gastrointestinal stromal tumors with internal tandem duplications in 3' end of KIT juxtamembrane domain occur predominantly in stomach and generally seem to have a favorable course. Mod Pathol (2003) 1.02
Early involvement of death-associated protein kinase promoter hypermethylation in the carcinogenesis of Barrett's esophageal adenocarcinoma and its association with clinical progression. Neoplasia (2007) 1.01
Epithelioid gastric stromal tumours of the antrum in young females with the Carney triad: a report of three new cases with mutational analysis and comparative genomic hybridization. Oncol Rep (2007) 1.01
Pitfalls in mutational testing and reporting of common KIT and PDGFRA mutations in gastrointestinal stromal tumors. BMC Med Genet (2010) 1.01
Promoter hypermethylation of p16INK4a, E-cadherin, O6-MGMT, DAPK and FHIT in adenocarcinomas of the esophagus, esophagogastric junction and proximal stomach. Int J Oncol (2005) 1.00
APC promoter methylation and protein expression in hepatocellular carcinoma. J Cancer Res Clin Oncol (2007) 0.99
Patterns of gene amplification in gastrointestinal stromal tumors (GIST). Lab Invest (2005) 0.99
Optimal lymph node harvest in rectal cancer (UICC stages II and III) after preoperative 5-FU-based radiochemotherapy. Acetone compression is a new and highly efficient method. Am J Surg Pathol (2012) 0.96
Overview of major classes of plant-derived anticancer drugs. Int J Biomed Sci (2009) 0.96
Alterations of G1-S checkpoint in chordoma: the prognostic impact of p53 overexpression. Cancer (2005) 0.96
Death-associated protein kinase controls STAT3 activity in intestinal epithelial cells. Am J Pathol (2013) 0.94
MDM2 gene amplification: a new independent factor of adverse prognosis in non-small cell lung cancer (NSCLC). Lung Cancer (2004) 0.93
CpG island methylator phenotype infers a poor disease-free survival in locally advanced rectal cancer. Surgery (2011) 0.93
Expression profile of the telomeric complex discriminates between benign and malignant pheochromocytoma. J Clin Endocrinol Metab (2003) 0.93
Promoter methylation of CDKN2A and lack of p16 expression characterize patients with hepatocellular carcinoma. BMC Cancer (2010) 0.92
Identification of phosphorylated p38 as a novel DAPK-interacting partner during TNFalpha-induced apoptosis in colorectal tumor cells. Am J Pathol (2009) 0.92
P16 alterations increase the metastatic potential of endometrial carcinoma. Gynecol Oncol (2008) 0.92
Methylation-dependent activation of CDX1 through NF-κB: a link from inflammation to intestinal metaplasia in the human stomach. Am J Pathol (2012) 0.91
Location-specific epigenetic regulation of the metallothionein 3 gene in esophageal adenocarcinomas. PLoS One (2011) 0.91
Metastatic Malignant Melanoma With Complete Loss of Differentiation Markers (Undifferentiated/Dedifferentiated Melanoma): Analysis of 14 Patients Emphasizing Phenotypic Plasticity and the Value of Molecular Testing as Surrogate Diagnostic Marker. Am J Surg Pathol (2016) 0.90
Sporadic segmental Interstitial cell of cajal hyperplasia (microscopic GIST) with unusual diffuse longitudinal growth replacing the muscularis propria: differential diagnosis to hereditary GIST syndromes. Int J Clin Exp Pathol (2010) 0.90
Cutting edge: Chk1 directs senescence and mitotic catastrophe in recovery from G₂ checkpoint arrest. J Cell Mol Med (2011) 0.89
Silencing of MGMT expression by promoter hypermethylation in the metaplasia-dysplasia-carcinoma sequence of Barrett's esophagus. Cancer Lett (2008) 0.89
Epigenetic and genetic silencing of CHFR in esophageal adenocarcinomas. Cancer (2010) 0.88
Insulin receptor, insulin receptor substrate-1, Raf-1, and Mek-1 during hormonal hepatocarcinogenesis by intrahepatic pancreatic islet transplantation in diabetic rats. Cancer Res (2004) 0.88
Establishment and characterization of the permanent human cell line C3842 derived from a secondary chondrosarcoma in Ollier's disease. Virchows Arch (2005) 0.87
Inhibition of tumor promotion by parthenolide: epigenetic modulation of p21. Cancer Prev Res (Phila) (2012) 0.87
Homozygous proline at codon 72 of p53 as a potential risk factor favoring the development of undifferentiated thyroid carcinoma. Int J Oncol (2002) 0.86
APC promoter hypermethylation is an early event in endometrial tumorigenesis. Cancer Sci (2009) 0.86
Prognostic value of MMP-2, -9 and TIMP-1,-2 immunoreactive protein at the invasive front in advanced head and neck squamous cell carcinomas. Pathol Res Pract (2002) 0.86
Helicobacter pylori regulates p21(WAF1) by histone H4 acetylation. Biochem Biophys Res Commun (2008) 0.86
Gallotannin inhibits NFĸB signaling and growth of human colon cancer xenografts. Cancer Biol Ther (2011) 0.86
The anticancer effect of saffron in two p53 isogenic colorectal cancer cell lines. BMC Complement Altern Med (2012) 0.86
Analysis of TP53 and PTEN in gliomatosis cerebri. Acta Neuropathol (2003) 0.85
Camel milk lactoferrin reduces the proliferation of colorectal cancer cells and exerts antioxidant and DNA damage inhibitory activities. Food Chem (2013) 0.84
Identification of DAPK as a scaffold protein for the LIMK/cofilin complex in TNF-induced apoptosis. Int J Biochem Cell Biol (2013) 0.84
ATF2 knockdown reinforces oxidative stress-induced apoptosis in TE7 cancer cells. J Cell Mol Med (2013) 0.84
Transcription control of DAPK. Apoptosis (2014) 0.84
INK4a-ARF alterations in Barrett's epithelium, intraepithelial neoplasia and Barrett's adenocarcinoma. Virchows Arch (2004) 0.84
Hereditary p16-Leiden mutation in a patient with multiple head and neck tumors. Am J Hum Genet (2003) 0.84
Hypermethylation of the CDKN2/p16INK4A promotor in thyroid carcinogenesis. Pathol Res Pract (2003) 0.83
Silencing of the maspin gene by promoter hypermethylation in thyroid cancer. Int J Mol Med (2003) 0.83
Region-specific analysis of mitochondrial DNA deletions in neurodegenerative disorders in humans. Neurosci Lett (2004) 0.83
DAPK and cytoskeleton-associated functions. Apoptosis (2014) 0.82
Pathogenetic Implications of BRAF Mutation Distribution in Stage IV Melanoma Patients. Dermatology (2015) 0.82
An unusual and potentially misleading phenotypic change in a primary gastrointestinal stromal tumour (GIST) under imatinib mesylate therapy. Virchows Arch (2010) 0.82
Retracted HSP90 is a key for telomerase activation and malignant transition in pheochromocytoma. Endocrine (2003) 0.82
CD97, CD95 and Fas-L clearly discriminate between chronic pancreatitis and pancreatic ductal adenocarcinoma in perioperative evaluation of cryocut sections. Pathol Int (2002) 0.82
DAPK plays an important role in panobinostat-induced autophagy and commits cells to apoptosis under autophagy deficient conditions. Apoptosis (2012) 0.82
Gastrointestinal stromal tumor presenting as a rectovaginal mass. Clinicopathologic and molecular-genetic characterization of a rare tumor with a literature review. Hum Pathol (2011) 0.80
Sensitive allele-specific real-time PCR test for mutations in BRAF codon V600 in skin melanoma. Melanoma Res (2014) 0.80
A novel complex KIT mutation in a gastrointestinal stromal tumor of the vermiform appendix. Hum Pathol (2012) 0.80
Loss of heterozygosity on chromosome 22q in gastrointestinal stromal tumors (GISTs): a study on 50 cases. Lab Invest (2005) 0.80
Maspin in thyroid cancer: its relationship with p53 and clinical outcome. Oncol Rep (2003) 0.80
Loss of heterozygosity of the retinoblastoma gene is correlated with the altered pRb expression in human endometrial cancer. Virchows Arch (2002) 0.80
Cell-cell communication by endocannabinoids during immune surveillance of the central nervous system. Results Probl Cell Differ (2006) 0.80
Defined morphological criteria allow reliable diagnosis of colorectal serrated polyps and predict polyp genetics. Virchows Arch (2014) 0.79
Comparison of intraperitoneal with intravenous administration of taxol in experimental peritoneal carcinomatosis. Chemotherapy (2007) 0.79
p16INK4A alterations are accompanied by aberrant protein immunostaining in endometrial carcinomas. J Cancer Res Clin Oncol (2003) 0.79
Apolipoprotein A-IV mRNA overexpression in early preneoplastic hepatic foci induced by low-number pancreatic islet transplants in streptozotocin-diabetic rats. Pathol Res Pract (2003) 0.78
P53/MDM2 overexpression in metastatic endometrial cancer: correlation with clinicopathological features and patient outcome. Clin Exp Metastasis (2007) 0.78
Regulation of MMP-9 by a WIN-binding site in the monocyte-macrophage system independent from cannabinoid receptors. PLoS One (2012) 0.78
Alterations of cell cycle regulators in gliomatosis cerebri. J Neurooncol (2005) 0.77
Trophoblast expression dynamics of the tumor suppressor gene gastrokine 2. Histochem Cell Biol (2015) 0.77
Single-cell analysis of mtDNA deletion levels in sporadic amyotrophic lateral sclerosis. Neuroreport (2004) 0.77
Apoptosis signalling activated by TNF in the lower gastrointestinal tract--review. Curr Pharm Biotechnol (2012) 0.77
Prognostic value of O-6-methylguanine-DNA methyltransferase loss in salivary gland carcinomas. Head Neck (2013) 0.77
Anorectal gastrointestinal stromal tumors: a retrospective multicenter analysis of 15 cases emphasizing their high local recurrence rate and the need for standardized therapeutic approach. Int J Colorectal Dis (2013) 0.77
Allelic loss at TP53 is not related to p53 protein overexpression in primary human endometrial carcinomas. Oncology (2005) 0.76
Telomerase activity in juxtacortical and conventional high-grade osteosarcomas: correlation with grade, proliferative activity and clinical response to chemotherapy. Cancer Lett (2003) 0.76
Function of HSP90 and p23 in the telomerase complex of thyroid tumors. Pathol Res Pract (2003) 0.76
Evaluation of molecular genetic alterations associated with tumor progression in a case of gliomatosis cerebri. J Neurooncol (2006) 0.76